{"id":"camrelizumab-plus-chemo-radiotherapy","safety":{"commonSideEffects":[{"rate":null,"effect":"Immune-related pneumonitis"},{"rate":null,"effect":"Immune-related hepatitis"},{"rate":null,"effect":"Immune-related colitis"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Nausea and vomiting"},{"rate":null,"effect":"Hematologic toxicity (anemia, leukopenia, thrombocytopenia)"}]},"_chembl":{"chemblId":"CHEMBL4297715","moleculeType":"Antibody"},"_fixedAt":"2026-03-30T13:21:28.825567","_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Camrelizumab binds to programmed death receptor-1 (PD-1) on T cells, preventing interaction with PD-L1/PD-L2 ligands on tumor cells and restoring anti-tumor immunity. When combined with chemotherapy and radiotherapy, the regimen leverages immunogenic cell death from chemo-radiation to amplify the checkpoint inhibition effect, creating a multi-modal attack on cancer cells.","oneSentence":"Camrelizumab is a PD-1 inhibitor that blocks immune checkpoint signaling to enhance anti-tumor T-cell responses, combined with chemotherapy and radiotherapy for synergistic cancer cell killing.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:04:44.692Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Locally advanced or metastatic nasopharyngeal carcinoma (in combination with chemotherapy and/or radiotherapy)"},{"name":"Other solid tumors in combination with chemo-radiotherapy (Phase 3 investigation)"}]},"_fixedFields":["pubmed(2)"],"trialDetails":[{"nctId":"NCT04928807","phase":"PHASE3","title":"Short-Course Radiotherapy Followed by Neoadjuvant Chemotherapy and Camrelizumab in Locally Advanced Rectal Cancer (UNION)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","startDate":"2021-07-20","conditions":"Rectal Cancer","enrollment":231},{"nctId":"NCT07432087","phase":"PHASE3","title":"Camrelizumab Combined With EGFR Monoclonal Antibody or Chemotherapy for Perioperative Treatment of Locally Advanced Head and Neck Squamous Cell Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"Yue He, MD","startDate":"2026-02-01","conditions":"Head and Neck Squamous Cell Carcinoma","enrollment":246},{"nctId":"NCT07397442","phase":"PHASE2","title":"Short-Course Radiotherapy Combined With Chemotherapy and Immunotherapy in Mid-Low Locally Advanced Rectal Cancer","status":"NOT_YET_RECRUITING","sponsor":"Beijing Friendship Hospital","startDate":"2026-03-01","conditions":"Rectal Cancer, Adenocarcinoma, Rectal Cancer Stage II, Rectal Cancer Stage III","enrollment":19},{"nctId":"NCT07332247","phase":"PHASE2","title":"PD-1 Inhibitor Plus Chemotherapy Followed by Immediate Versus Selective Re-irradiation for Locally Advanced Recurrent NPC","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2026-02-03","conditions":"Nasopharangeal Cancer, Recurrent Nasopharynx Carcinoma","enrollment":94},{"nctId":"NCT07162506","phase":"PHASE2","title":"DCRT vs. Surgery in Resectable ESCC Patient Achiving cCR/PR After nCI","status":"RECRUITING","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2025-08-01","conditions":"Esophageal Cancer","enrollment":120},{"nctId":"NCT06866951","phase":"PHASE2, PHASE3","title":"A Clinical Study Comparing Chemotherapy Combined With PD-1 Inhibitor Versus Concurrent Chemoradiotherapy in Cervical Cancer Patients With Positive Lymph Nodes After Surgery: A Multicenter Randomized Controlled Clinical Trial","status":"WITHDRAWN","sponsor":"Women's Hospital School Of Medicine Zhejiang University","startDate":"2025-03-01","conditions":"Cervical Cancers","enrollment":""},{"nctId":"NCT07235319","phase":"PHASE3","title":"PD-1 Inhibitor Plus Chemotherapy Followed by Immediate Versus Salvage Locoregional Radiotherapy in De Novo Metastatic NPC","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2025-11-20","conditions":"Nasopharangeal Cancer, Distant Metastasis","enrollment":260},{"nctId":"NCT07236320","phase":"NA","title":"Neoadjuvant Immunochemotherapy vs Chemoradiotherapy in ESCC","status":"COMPLETED","sponsor":"Yongtao Han","startDate":"2018-03-01","conditions":"Esophageal Squamous Cell Carcinoma (ESCC)","enrollment":200},{"nctId":"NCT06869226","phase":"PHASE2","title":"A Multicenter Phase II Clinical Study of Neoadjuvant Use of Camrelizumab in Combination With Chemotherapy for Organ Preservation in Esophageal Cancer","status":"RECRUITING","sponsor":"Peking University Cancer Hospital & Institute","startDate":"2025-04-30","conditions":"Esophageal Cancer","enrollment":283},{"nctId":"NCT06145308","phase":"PHASE2","title":"Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular Typing","status":"RECRUITING","sponsor":"Peking Union Medical College","startDate":"2023-08-15","conditions":"Salivary Gland Carcinoma, Precision Therapy","enrollment":39},{"nctId":"NCT07057089","phase":"PHASE2","title":"Involved-field Radiotherapy-TNT Combined With PD-1 Inhibitor for pMMR Locally Advanced Rectal Cancer (Neo-Field I)","status":"RECRUITING","sponsor":"Hebei Medical University Fourth Hospital","startDate":"2025-07-01","conditions":"Locally Advanced Rectal Cancer","enrollment":90},{"nctId":"NCT06435260","phase":"PHASE2","title":"Hypofractionated Radiotherapy +Chemotherapy+ Camrelizumab as Neoadjuvant Therapy for Pancreatic Cancer","status":"RECRUITING","sponsor":"Hebei Medical University Fourth Hospital","startDate":"2024-08-01","conditions":"Pancreatic Cancer","enrollment":30},{"nctId":"NCT07016737","phase":"PHASE3","title":"Immunochemotherapy ± Salvage Chemoradiation for Local Recurrence of Esophageal Squamous Cell Carcinoma After Definitive Chemoradiotherapy","status":"ENROLLING_BY_INVITATION","sponsor":"Ye jinjun","startDate":"2024-08-01","conditions":"Esophageal Squamous Cell Carcinoma (ESCC)","enrollment":79},{"nctId":"NCT06926179","phase":"","title":"Safety, Efficacy, and Survival Outcomes of Neoadjuvant/Induction Immunotherapy in Surgical and Radiotherapeutic Management of Non-Small Cell Lung Cancer","status":"RECRUITING","sponsor":"Peking University Cancer Hospital & Institute","startDate":"2024-12-01","conditions":"Lung Cancer (NSCLC), Neoadjuvant Immunotherapy, Radiotherapy","enrollment":500},{"nctId":"NCT06901622","phase":"PHASE2","title":"Camrelizumab and Chemotherapy With or Without Anlotinib as First-line Treatment for Advanced Gallbladder Cancer and Extrahepatic Cholangiocarcinoma","status":"ENROLLING_BY_INVITATION","sponsor":"The First Affiliated Hospital of Zhengzhou University","startDate":"2024-11-08","conditions":"Gallbladder Cancer and Extrahepatic Cholangiocarcinoma","enrollment":50},{"nctId":"NCT04649476","phase":"PHASE2","title":"Neoadjuvant PD-1 Blockade in Resectable Oral Squamous Cell Carcinoma","status":"COMPLETED","sponsor":"Hospital of Stomatology, Wuhan University","startDate":"2021-03-22","conditions":"Oral Squamous Cell Carcinoma","enrollment":68},{"nctId":"NCT06675214","phase":"PHASE3","title":"Under Whole-course of Immunotherapy, Gradient Fractionated RT with CCT Versus CFRT with CCT for LANPC Who Achieved PR Post Induction Chemotherapy.","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2024-07-30","conditions":"Nasopharyngeal Carcinoma, De-escalation Therapy","enrollment":586},{"nctId":"NCT06288373","phase":"PHASE2, PHASE3","title":"Neoadjuvant Chemoimmunotherapy Versus Concurrent Chemoradiotherapy for LACC","status":"RECRUITING","sponsor":"Tongji Hospital","startDate":"2024-04-22","conditions":"Cervical Cancer, Locally Advanced Cervical Cancer, Concurrent Chemoradiotherapy","enrollment":440},{"nctId":"NCT05043688","phase":"PHASE3","title":"Camrelizumab Plus Neoadjuvant Chemotherapy or Chemoradiotherapy Versus Chemoradiotherapy in Resectable ESCC.","status":"RECRUITING","sponsor":"Zhigang Li","startDate":"2021-09-01","conditions":"Resectable Esophageal Squamous Cell Carcinoma","enrollment":426},{"nctId":"NCT05554276","phase":"PHASE2","title":"Neoadjuvant Chemotherapy Combined With PD-1 + Radical Radiotherapy in Locally Advanced Cervical Cancer","status":"RECRUITING","sponsor":"Shanghai Jiao Tong University Affiliated Sixth People's Hospital","startDate":"2023-08-01","conditions":"Neoadjuvant Chemotherapy, PD-1 Antibody, Radiotherapy","enrollment":36},{"nctId":"NCT06516445","phase":"PHASE2","title":"SCRT Followed by Camrelizumab Combined With Fluzoparib and Chemotherapy as Neoadjuvant Therapy for LARC","status":"RECRUITING","sponsor":"Huazhong University of Science and Technology","startDate":"2023-06-28","conditions":"Colorectal Cancer","enrollment":33},{"nctId":"NCT06086457","phase":"PHASE3","title":"PD-1 Inhibitor Plus Chemotherapy With or Without Radiotherapy in Patients With Metastatic Esophageal Cancer","status":"RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2024-02-04","conditions":"Esophageal Neoplasms","enrollment":436},{"nctId":"NCT06438627","phase":"PHASE3","title":"Efficacy and Safety of TPC+Apatinib+Camrelizumab vs GP+ Camrelizumab for High-Risk Nasopharyngeal Carcinoma: A Phase 3 Trial","status":"RECRUITING","sponsor":"XIANG YANQUN","startDate":"2024-05-30","conditions":"Nasopharyngeal Carcinoma","enrollment":164},{"nctId":"NCT04715633","phase":"PHASE2","title":"PD-1 Inhibitors Combined With VEGF Inhibitors for Locally Advanced dMMR/MSI-H Colorectal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2020-12-01","conditions":"Colorectal Cancer, Microsatellite Instability High","enrollment":53},{"nctId":"NCT06339060","phase":"PHASE3","title":"An Organ Preservation Strategies After Chemoradiotherapy Combined With Immunotherapy for Esophageal Cancer (PALACE3).","status":"RECRUITING","sponsor":"Ruijin Hospital","startDate":"2024-05-01","conditions":"Esophageal Cancer","enrollment":356},{"nctId":"NCT06084897","phase":"PHASE2","title":"Radiotherapy in Patients With Metastatic Esophageal Cancer Responding to PD-1 Inhibitor Plus Chemotherapy","status":"RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2023-10-16","conditions":"Esophageal Neoplasm Metastatic, Esophageal Cancer Stage IVb","enrollment":120},{"nctId":"NCT05128201","phase":"PHASE2","title":"Consolidative Radiotherapy Combined With Camrelizumab and Chemotherapy for Oligometastatic Nasopharyngeal Carcinoma","status":"RECRUITING","sponsor":"Jiangxi Provincial Cancer Hospital","startDate":"2021-12-01","conditions":"Oligometastatic Disease","enrollment":63},{"nctId":"NCT06354530","phase":"PHASE2, PHASE3","title":"A Study of Neoadjuvant Therapy for the Treatment of Patients With Locally Advanced Esophageal Squamous Cell Carcinoma","status":"RECRUITING","sponsor":"Army Medical Center of PLA","startDate":"2024-03-08","conditions":"Neoadjuvant Therapy, Esophageal Squamous Cell Carcinoma","enrollment":266},{"nctId":"NCT05798793","phase":"PHASE3","title":"Neoadjuvant Anti-PD-1 Immunotherapy With Chemotherapy in Resectable Locally Advanced Oral Squamous Cell Carcinoma","status":"RECRUITING","sponsor":"Hospital of Stomatology, Wuhan University","startDate":"2023-11-21","conditions":"Oral Squamous Cell Carcinoma","enrollment":309},{"nctId":"NCT06304545","phase":"PHASE2","title":"Treatment of Rectal Cancer With Long-term Concurrent Chemoradiotherapy Combined With Camrelizumab","status":"NOT_YET_RECRUITING","sponsor":"Harbin Medical University","startDate":"2024-03-15","conditions":"Rectal Cancer","enrollment":48},{"nctId":"NCT06163729","phase":"PHASE2","title":"Camrelizumab Combined With Chemotherapy and Radiotherapy Perioperative Treatment of Esophageal Gastric Junction Adenocarcinoma","status":"RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2022-08-25","conditions":"Gastroesophageal Junction Adenocarcinoma (Siewert II-III)","enrollment":68},{"nctId":"NCT04558684","phase":"PHASE1, PHASE2","title":"Radiotherapy With Neoadjuvant Chemotherapy and Immunotherapy in Rectal Cancer","status":"SUSPENDED","sponsor":"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","startDate":"2019-11-01","conditions":"Rectal Cancer, Radiotherapy, Immunotherapy","enrollment":30},{"nctId":"NCT06170697","phase":"PHASE2","title":"Advanced First-line Treatment of Short-term Postoperative Progression of Head and Neck Squamous Cell Carcinoma","status":"UNKNOWN","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2023-03-01","conditions":"Head and Neck Squamous Cell Carcinoma","enrollment":46},{"nctId":"NCT06092957","phase":"PHASE3","title":"Reduced-dose RT With/Without CCT Versus Standard CCRT for High-risk LANPC Who Achieved CR Post Induction Chemotherapy","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2023-10-09","conditions":"Nasopharyngeal Carcinoma, De-escalation Therapy","enrollment":504},{"nctId":"NCT06143722","phase":"PHASE2","title":"Synchronous or Sequential Radiotherapy for Advanced Esophageal Squamous Cell Carcinoma With Oligometastases.","status":"NOT_YET_RECRUITING","sponsor":"West China Hospital","startDate":"2023-11-30","conditions":"Advanced Esophageal Squamous Carcinoma With Oligometastases","enrollment":63},{"nctId":"NCT06121700","phase":"PHASE2","title":"Radiotherapy + Chemoimmunotherapy Followed by Surgery in Patients With Limited Metastatic Gastric or GEJ Cancer","status":"RECRUITING","sponsor":"Fudan University","startDate":"2023-01-01","conditions":"Adenocarcinoma, Stomach Neoplasm, Gastroesophageal-junction Cancer","enrollment":55},{"nctId":"NCT05624099","phase":"PHASE2","title":"Camrelizumab Combined With Chemoradiotherapy in Advanced Esophageal Cancer.","status":"RECRUITING","sponsor":"Fujian Cancer Hospital","startDate":"2023-08-01","conditions":"Esophageal Neoplasms, Esophageal Diseases, Digestive System Neoplasms","enrollment":75},{"nctId":"NCT06048926","phase":"NA","title":"Carrelizumab Combined With Concurrent Radiotherapy and Chemotherapy for Unresectable Esophageal Squamous Cell Carcinoma","status":"ENROLLING_BY_INVITATION","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2022-07-30","conditions":"Esophageal Squamous Cell Carcinoma","enrollment":30},{"nctId":"NCT06031597","phase":"PHASE3","title":"Radiotherapy Combined With ICIs as Treatment for LA-NSCLC After Failing Induction Immunochemotherapy","status":"UNKNOWN","sponsor":"Zhejiang Cancer Hospital","startDate":"2023-09-15","conditions":"Non-small Cell Lung Cancer Stage III","enrollment":105},{"nctId":"NCT04156698","phase":"PHASE2","title":"Induction Chemotherapy Combined With Immunotherapy for Locally Advanced Hypopharyngeal Carcinoma","status":"UNKNOWN","sponsor":"Eye & ENT Hospital of Fudan University","startDate":"2020-05-21","conditions":"Hypopharyngeal Carcinoma, Immunotherapy, Chemotherapy","enrollment":51},{"nctId":"NCT05213884","phase":"PHASE2","title":"The Efficacy of Induction and Adjuvant Camrelizumab Combined With Chemoradiation for LA-HNSCC","status":"RECRUITING","sponsor":"Chongqing University Cancer Hospital","startDate":"2022-01-01","conditions":"Head and Neck Squamous Cell Carcinoma","enrollment":30},{"nctId":"NCT05821452","phase":"PHASE2","title":"Immunotherapy Plus Chemotherapy vs. Chemoradiotherapy for Thoracic Squamous Esophageal Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"Fujian Medical University Union Hospital","startDate":"2023-05-25","conditions":"Chemotherapy, Radiation Therapy","enrollment":40},{"nctId":"NCT05097209","phase":"PHASE2","title":"Camrelizumab for the Treatment of Locally Advanced Nasopharyngeal Carcinoma","status":"RECRUITING","sponsor":"Wei Jiang","startDate":"2022-04-06","conditions":"Nasopharyngeal Carcinoma","enrollment":200},{"nctId":"NCT05772208","phase":"PHASE3","title":"Intensified Treatments for Patients With Locally Advanced Nasopharyngeal Carcinoma With Detectable EBV DNA After One Cycle GP Regime Neoadjuvant Chemotherapy","status":"RECRUITING","sponsor":"Fudan University","startDate":"2022-01-01","conditions":"Nasopharyngeal Carcinoma","enrollment":459},{"nctId":"NCT04365049","phase":"","title":"Nab-Paclitaxel and Gemcitabine Plus Camrelizumab and Radiotherapy for Locally Advanced Pancreatic Adenocarcinoma","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2020-04-01","conditions":"PDAC - Pancreatic Ductal Adenocarcinoma","enrollment":100},{"nctId":"NCT05650216","phase":"PHASE2","title":"Camrelizumab Combined With Neoadjuvant Concurrent Chemoradiotherapy for Resectable Locally Advanced ESCC（NICE-RT）","status":"UNKNOWN","sponsor":"Shanghai Chest Hospital","startDate":"2022-12-25","conditions":"Esophageal Squamous Cell Carcinoma","enrollment":50},{"nctId":"NCT05507411","phase":"PHASE2","title":"Watch and Wait for NeoAdjuvant Concurrent Radiochemotherapy Combined With Camrelizumab in Patients With Resectable ESCC","status":"RECRUITING","sponsor":"Zhejiang Cancer Hospital","startDate":"2022-08-03","conditions":"Esophageal Squamous Cell Carcinoma","enrollment":100},{"nctId":"NCT05472467","phase":"PHASE2","title":"Camrelizumab Combination With SBRT and Concurrent Chemotherapy Treated Stage IV Oligometastatic Non-small Cell Lung Cancer","status":"UNKNOWN","sponsor":"Sichuan Cancer Hospital and Research Institute","startDate":"2021-12-21","conditions":"Non-small Cell Lung Cancer Metastatic","enrollment":35},{"nctId":"NCT05431764","phase":"PHASE2","title":"Whole-target Consolidation Therapy Under Systemic Therapy for Oligometastatic Nasopharyngeal Carcinoma","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2022-06-20","conditions":"Nasopharyngeal Carcinoma","enrollment":38},{"nctId":"NCT04878107","phase":"PHASE2","title":"SBRT/LDRT in Combination With Camrelizumab and Apatinib in Metastatic Non-small Cell Lung Cancer Patient Previously Treated With PD-1/L1 Inhibitor and Chemotherapy","status":"UNKNOWN","sponsor":"Wuhan University","startDate":"2022-03-15","conditions":"Non-Small Cell Lung Cancer","enrollment":88},{"nctId":"NCT04143984","phase":"PHASE2","title":"Carbon-Ion Radiotherapy Plus Camrelizumab for Locally Recurrent Nasopharyngeal Carcinoma","status":"UNKNOWN","sponsor":"Shanghai Proton and Heavy Ion Center","startDate":"2021-01-19","conditions":"Nasopharyngeal Carcinoma","enrollment":146},{"nctId":"NCT04390945","phase":"PHASE2","title":"Camrelizumab Combined With CRT for Treatment of Patients With Local Recurrence of Esophageal Cancer","status":"UNKNOWN","sponsor":"The First Affiliated Hospital of Henan University of Science and Technology","startDate":"2021-12-01","conditions":"Esophageal Cancer","enrollment":62},{"nctId":"NCT05183958","phase":"PHASE2","title":"A Multicenter, Randomized Controlled, Phase II Clinical Study of First-line Chemotherapy and Camrelizumab With or Without Radiotherapy in the Treatment of Oligometastatic Esophageal Cancer","status":"UNKNOWN","sponsor":"Zhejiang Cancer Hospital","startDate":"2021-12-31","conditions":"Esophageal Cancer","enrollment":118},{"nctId":"NCT04539600","phase":"PHASE2","title":"Induction Chemotherapy Combined With Camrelizumab in Locoregionally Advanced Hypopharyngeal Cancer","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2020-11-01","conditions":"Hypopharyngeal Cancer, Immunotherapy, Induction Chemotherapy","enrollment":23},{"nctId":"NCT04884906","phase":"PHASE2","title":"Camrelizumab Combined With Radiotherapy and Chemotherapy for the Treatment of Recurrent or Metastatic Cervical Cancer","status":"UNKNOWN","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2020-11-01","conditions":"Locally Advanced Cervical Cancer","enrollment":40},{"nctId":"NCT04828395","phase":"PHASE2","title":"Fluzoparib Combined With Camrelizumab for Maintenance Treatment of Locally Advanced Non-small Cell Lung Cancer","status":"UNKNOWN","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2021-03-01","conditions":"Non-small Cell Lung Cancer","enrollment":65},{"nctId":"NCT04768075","phase":"PHASE3","title":"Camrelizumab Combined With SRT/WBRT and Chemotherapy in Patients With Brain Metastases of Driven Gene-negative NSCLC","status":"UNKNOWN","sponsor":"Guangdong Association of Clinical Trials","startDate":"2021-03-05","conditions":"Non-Small-Cell Lung Cancer","enrollment":200},{"nctId":"NCT04231552","phase":"PHASE1, PHASE2","title":"Preoperative Short Course Radiotherapy With Chemotherapy and Camerelizumab in Locally Advanced Rectal Cancer","status":"UNKNOWN","sponsor":"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","startDate":"2019-11-10","conditions":"Rectal Cancer, Radiotherapy, Immunotherapy","enrollment":30},{"nctId":"NCT04453826","phase":"PHASE3","title":"Concurrent and Adjuvant PD1 Treatment Combined With Chemo-radiotherapy for High-risk Nasopharyngeal Carcinoma","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2020-09-01","conditions":"Nasopharyngeal Cancer, Chemotherapy, Radiotherapy","enrollment":388},{"nctId":"NCT04512417","phase":"PHASE2","title":"A Clinical Study Of Camrelizumab With Or Without Radiotherapy In The Treatment Of Esophageal Cancer","status":"UNKNOWN","sponsor":"Zhejiang Cancer Hospital","startDate":"2020-08-31","conditions":"Esophageal Cancer","enrollment":63},{"nctId":"NCT04340401","phase":"PHASE2","title":"Total Neoadjuvant Treatment Plus SHR1210 for High-risk Rectal Cancer and Biomarker Screening Base on Neoantigen","status":"UNKNOWN","sponsor":"Peking University Cancer Hospital & Institute","startDate":"2020-05-25","conditions":"Rectal Cancer","enrollment":25},{"nctId":"NCT04333927","phase":"PHASE2","title":"Adjuvant Immunotherapy Combined With Chemoradiation for Patients With High-risk reseCtable Extrahepatic chOlangiocaRcinoma and gallblaDder Cancer","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2020-06-01","conditions":"Biliary Tract Cancer, Extrahepatic Cholangiocarcinoma, Gallbladder Cancer","enrollment":92},{"nctId":"NCT03817658","phase":"PHASE2","title":"A Phase II Study of SHR-1210 vs Placebo as Consolidation Chemotherapy After Radical Concurrent Chemoradiotherapy in Locally Advanced ESCC","status":"UNKNOWN","sponsor":"The First Affiliated Hospital of Zhengzhou University","startDate":"2019-10","conditions":"Esophageal Squamous Cell Carcinoma","enrollment":725},{"nctId":"NCT03671265","phase":"NA","title":"Combination of Chemotherapy Plus RT and SHR-1210 to Treat Patients With ESCC","status":"UNKNOWN","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2018-09-17","conditions":"Esophageal Cancer","enrollment":20}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"recentPublications":[{"date":"2024 Jun 19","pmid":"38898018","title":"Camrelizumab-based induction chemoimmunotherapy in locally advanced stage hypopharyngeal carcinoma: phase II clinical trial.","journal":"Nature communications"},{"date":"2020 Nov","pmid":"32814482","title":"Camrelizumab plus apatinib successfully treated a patient with advanced esophageal squamous cell carcinoma.","journal":"Immunotherapy"}],"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Camrelizumab plus chemo-radiotherapy","genericName":"Camrelizumab plus chemo-radiotherapy","companyName":"Sun Yat-sen University","companyId":"sun-yat-sen-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Camrelizumab is a PD-1 inhibitor that blocks immune checkpoint signaling to enhance anti-tumor T-cell responses, combined with chemotherapy and radiotherapy for synergistic cancer cell killing. Used for Locally advanced or metastatic nasopharyngeal carcinoma (in combination with chemotherapy and/or radiotherapy), Other solid tumors in combination with chemo-radiotherapy (Phase 3 investigation).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}